Immunosuppressive drugs

Immunosuppressive drugs

Pharmaceutical form and use

ATC group

Drug name

COVID vaccination

Tablets, daily use

L04AA

Mycophenolic acid, Rapamune, Certican, Arava, Gilenya, Xeljanz, Aubagio, Otezla, Olumiant, Mayzent

Yes. All vaccines are eligible, no change in treatment due to vaccination unless the treating physician recommends a change.

L04AD

Sandimmun, tacrolimus (e.g. Prograf)

L04AX

Imurel, thalidomide, methotrexate, Esbriet, Tecfidera

H02AB

Steroids, e.g. hydrocortisone

Yes. All vaccines are eligible, no change in treatment due to vaccination unless the treating physician recommends a change. Note that individuals with cortisol deficiency may need to increase their doses due to vaccination.

Tablets, irregular use

L04AA

Mavenclad

In consultation with the treating physician, vaccination may need to be scheduled individually, such as according to blood levels. See also here.

L04AX

Lenalidomid, Imnovid

Intravenous infusion administered approx. every 4 weeks

L04AA

Tysabri, Orencia, Entyvio

In consultation with treating physician, see also here.

L04AC

RoActemra, Cosentyx

Intravenous infusion or injection administered at intervals of less than 3 months

L04AB

Infliximab (e.g. Flixabi)

Yes. Vaccines should be used with as little time as possible between doses, and the timing of the first vaccination should be approx. when it is time for a dose and vaccination should be completed before the dose is administered if possible.

L04AC

Stelara, Ilaris, Tremfya

Intravenous infusion or injection administered approx. every 3–6 months

L04AA

Ocrevus

Yes. Vaccines should be used with as little time as possible between doses, and the timing of the first vaccination should be approx. 4–5 weeks before it is time for a dose and vaccination should be completed before the dose is administered.

Subcutaneous injection daily, can be administered at home

L04AC

Anakinra (Kineret)

Yes. All vaccines are eligible, no change in treatment due to vaccination unless the treating physician recommends a change.

Subcutaneous injection, usually approx. every 2 weeks, can be administered at home

L04AA

Benlysta

Yes. All vaccines are eligible. No need to skip a dose, schedule vaccination in between doses.

L04AB

Etanercept (Benepali, Enbrel), adalimumab (Humira, Imraldi, etc.), golimumab (Simponi)

Yes. All vaccines are eligible. Vaccination should be scheduled when it is time for a dose and that dose should be skipped, but the next dose should be taken according to schedule. If is not considered desirable to skip a dose, vaccination may be given in between doses.

L04AC

Kyntheum, Taltz

Infusion, irregular use

L04AC

Basiliximab

All vaccines are eligible, but circumstances may call for one rather than another. It is desirable to give the first dose of vaccine when 6 months have elapsed from administration but at least 2 weeks after the last dose and preferably 2–4 weeks before re-administration of drugs in these groups and in consultation with the treating physician.

L01XC02

Rituximab (e.g. MabThera)

This table is prepared by the Chief Epidemiologist in consultation with specialists who use these drugs, i.a. rheumatologists, hematologists, neurologists and nephrologists.


Fyrst birt 04.01.2022
Síðast uppfært 04.01.2022

<< Til baka